Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Poulvac Procerta HVT-IBD
- Development stage
- Unknown
- Lead developer
- Zoetis
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, In Ovo
01
Overview
Poulvac Procerta HVT-IBD is a veterinary vaccine for poultry that uses a recombinant serotype 3 turkey herpesvirus (HVT) as a vector to express the VP2 protein of infectious bursal disease virus (IBDV). This live, cell-associated vaccine is designed for active immunization of chickens and embryonated chicken eggs to reduce mortality, clinical signs, and lesions caused by Marek’s disease virus and to prevent mortality and clinical signs while reducing lesions caused by infectious bursal disease virus. The mechanism involves the expression of IBDV VP2 antigen via the non-pathogenic turkey herpesvirus vector in vaccinated birds, stimulating protective immunity against both diseases. The product is administered either subcutaneously to day-old chicks or in ovo to 18–19-day-old embryonated eggs. Developed specifically for poultry health management programs, it provides early onset protection with at least 63 days’ duration against IBDV[2][3][6][8].
- Brand names
- Poulvac Procerta HVT-IBD
- Other names
- Bursal Disease-Marek’s Disease Vaccine, Serotype 3, Live Marek’s Disease Vector
02
Targets
Host adaptive immune receptors recognizing Infectious Bursal Disease Virus VP2VP2 (Infectious bursal disease virus VP2 protein)
Beyond the preview
Go deeper on Poulvac Procerta HVT-IBD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Poulvac Procerta HVT-IBD.